Answers are grounded in this paper and cite their sources.
Background The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI), is the largest aggregation of histopathology-specific, population-based data for primary brain and other central nervous system tumors (BTs) in the United States. Summarized are the key findings from the 2025 CBTRUS annual statistical report and additional clinically relevant statistics for neuro-oncology healthcare providers. Methods CBTRUS incidence data are an aggregation of 48 central cancer registries (CCRs) from the CDC’s National Program of Cancer Registries (NPCR) and 4 CCRs from the NCI’s Surveillance, Epidemiology, and End Results Program covering the entire US population. Puerto Rico was excluded. Survival data were obtained from 43 NPCR CCRs. Mortality data were obtained from the National Vital Statistics System. All incidence and mortality rates were age-adjusted using the 2000 US standard population. Relative survival was estimated using the life table method. Overall survival was estimated using Kaplan–Meier models. Results The average annual age-adjusted incidence rate of all BTs was 26.05 per 100 000 population. Incidence was higher among females and non-Hispanic Black individuals. The most common malignant tumors were gliomas. The most common non-malignant tumors were low-grade meningiomas. Mortality rates and median survival varied by age, sex, and tumor type. Conclusions This summary describes the most up-to-date population-based incidence, mortality, and survival of primary BT types in the United States with an age-focused analysis and aims to serve as a concise resource for neuro-oncology healthcare providers.
No takes yet. Share an insight, caveat, or question.
Nisnboym et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: